TY - JOUR T1 - Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00469-2022 SP - 00469-2022 AU - Manuela Funke-Chambour AU - Namrata Kewalramani AU - Carlos Machahua AU - Venerino Poletti AU - Athol U. Wells AU - Jacques Cadranel Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/09/22/23120541.00469-2022.abstract N2 - The corresponding authors questioned our suggestions for second line LC therapy in fILD (Lung Cancer in fibrotic Interstitial Lung Disease) with vinorelbine (squamous cell carcinoma), and pemetrexed (adenocarcinoma). They suggest docetaxel rather than vinorelbine and pemetrexed, but there are opposing arguments. They refer to acute exacerbation rates from one retrospective nationwide surveillance of 396 patients with idiopathic interstitial pneumonia (IIP) and lung cancer in Japan [1]. However, this study does not reflect experience in other populations and regions.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Funke-Chambour reports grants from Boehringer Ingelheim, grants from Roche, other from MSD, outside the submitted work.Conflict of interest: Dr. Kewalramani reports grants and non-financial support from CSL Behring, from null, outside the submitted work.Conflict of interest: Dr. Machahua has nothing to disclose.Conflict of interest: Dr. Poletti reports personal fees from Boerhinger Ing, personal fees from Roche, personal fees from AMBU, personal fees from ERBE, outside the submitted work.Conflict of interest: Dr. Wells reports personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Bayer and Roche Pharmaceuticals, personal fees from Blade, outside the submitted work.Conflict of interest: Dr. Cadranel reports fees for participation to boards of experts for the development of cancer drugs from AbbVie, AZ, BI, BMS, Jansen, MSD, Novartis, Pfizer, Roche and Takeda. ER -